Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019163 (
hepatitis B
)
38,309
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We demonstrated that MIF-1, identified initially as a binding activity that associated with the intron I element of the
c-myc
gene, consists of two polypeptides, the myc intron-binding peptide (MIBP1) and the major histocompatibility class II promoter-binding protein, RFX1. Using a polyclonal antiserum directed against either oligonucleotide affinity-purified MIBP1 or a peptide derived from RFX1, we showed that MIBP1 and RFX1 are distinct molecules that associate in vivo and are both present in DNA-protein complexes at the
c-myc
(MIF-1) and major histocompatibility complex class II (RFX1) binding sites. We have also found that MIBP1 and RFX1 bind to a regulatory site (termed EP) required for enhancer activity of
hepatitis B
virus. In addition, we have identified MIF-1-like sequences within regulatory regions of several other viral genes and have shown that MIBP1 binds to these sites in cytomegalovirus, Epstein-Barr virus, and polyomavirus. We have also demonstrated that the MIF-1 and EP elements can function as silencers in the hepatocarcinoma HepG2 and the cervical carcinoma HeLa cell lines. These findings indicate that MIBP1 and EP/RFX1 can associate in vivo and may regulate the expression of several distinct cellular and viral genes.
...
PMID:The myc intron-binding polypeptide associates with RFX1 in vivo and binds to the major histocompatibility complex class II promoter region, to the hepatitis B virus enhancer, and to regulatory regions of several distinct viral genes. 776 Aug
We have established two cell lines of hepatocellular carcinoma [Hep-KANO, clone 1 (CL-1) and clone 2 (CL-2)] from tissue obtained at autopsy of a
hepatitis B
virus (HBV) carrier without histological signs of hepatitis or liver cirrhosis. These cell lines differed considerably from each other in morphology, proliferation pattern, alpha-fetoprotein secretion, albumin synthesis, cytokine secretion, modal chromosome number and transplantability to nude mice. Histologic examinations also revealed differences between them. Amplification of N-myc, L-myc, H-ras, K-ras, N-ras, c-erb-B and c-erb-B-2 and rearrangement of p53 were not found in either of the cell lines. However, CL-1 and CL-2 showed an identical HBV-DNA integration pattern. A 4-fold amplification of
c-myc
was observed in CL-1, but not in CL-2. Hep-KANO cell lines, CL-1 and CL-2 may be useful in clarifying the question of whether hepatocarcinogenesis is directly caused by HBV infection.
...
PMID:Characteristics of human hepatocellular carcinoma cell lines (Hep-KANO) derived from a non-hepatitic, non-cirrhotic hepatitis B virus carrier. 782 95
A series of changes in the genes that control hepatocyte growth, or interference with the protein products of these genes, appears to have an important role in the etiology of hepatocellular carcinoma (HCC). Mutations of the p53 tumor suppressor gene have been identified in 30-50% of HCC patients in some geographic areas. Abnormalities of the RB tumor suppressor gene have been found in 20-25% of HCCs, including 80-86% of HCCs with p53 mutations. Overexpression of transforming growth factor alpha (TGF-alpha), insulin-like growth factor II (IGF-II), and the oncogenes N-ras,
c-myc
, and c-fos have been found in high percentages of HCC patients. The cumulative effect of these changes may be more important than the order in which they occur. Some of these changes may explain the mechanism(s) by which the
hepatitis B
virus participates in the development of HCC.
...
PMID:Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma. 804 25
We have shown by transient transfection assays that c-Abl increases expression of a
c-myc
promoter construct although to a lesser extent than v-Abl. c-Abl has been reported to bind to a specific DNA sequence, the EP element, in the
hepatitis B
virus enhancer. A similar sequence exists in the promoter region of the
c-myc
gene, and we have identified a potential protein binding site in this region by in vivo footprinting. Gel shift analysis demonstrated that the
hepatitis B
virus enhancer and
c-myc
sites yield identical complexes. To determine whether c-Abl activates
c-myc
transcription by binding directly to the promoter region, several experiments were performed. Mutation of the EP site in the
c-myc
promoter had no effect on transcriptional activation of
c-myc
by c-Abl. Next, we demonstrated that the DNA binding domain of c-Abl was not required for the transcriptional activation of
c-myc
. Finally, by Western blot analysis, we have determined that c-Abl is not present in the gel shift complexes formed by either the
hepatitis B
virus enhancer or
c-myc
promoter. We conclude that c-Abl activates
c-myc
transcription indirectly with no requirement for DNA binding by c-Abl. We also find no evidence for the interaction of c-Abl with the EP sequence of either the
hepatitis B
virus enhancer or the
c-myc
promoter.
...
PMID:Activation of c-myc expression by c-Abl is independent of both the DNA binding function of c-Abl and the c-myc EP site. 806 36
Chronic hepadnavirus infection is associated with hepatocellular carcinoma (HCC) in natural hosts such as humans, woodchucks, and Beechey ground squirrels. Several possible oncogenic mechanisms have been identified, including a potential role of the hepadnavirus x (hbx) gene, which transactivates transcription regulated by certain cis-acting sequences, e.g. regulatory sequences of the
hepatitis B
virus (HBV) and heterologous regulatory sequences of other viruses and cellular genes. The oncogenic potential of hbx is suggested by the observation of HCCs in hbx transgenic mice, the oncogenic transformation of cells expressing hbx in culture, and the transactivation of oncogenes
c-myc
and c-jun by hbx. Cis-activation of cellular oncogenes N-myc and
c-myc
by viral promoter insertion has been a common finding in woodchuck hepatitis virus (WHV)-associated HCCs of woodchucks. No such cis-activation of any cellular gene has been shown in virus-associated HCCs of ground squirrels or humans. Amplification and overexpression of the
c-myc
gene has been a common finding in HCCs of ground squirrels, and is rare in woodchuck or human HCCs. Point mutations in the p53 gene and allelic deletion of p53 have been common findings in human HCCs, but have not been found in HCCs in woodchucks and have been found rarely in ground squirrels. How each of these genetic changes in the different hosts contributes to HCC remains to be determined, but apparently different changes in different HCCs of hepadnavirus-infected hosts suggest that several separate genetic events may contribute to the development of HCC. These events may differ in each host, and some may not result from a direct virus-specific mechanism. Chronic hepadnavirus infection is often associated with chronic necroinflammatory liver disease and cirrhosis, a pathologic process common to several other risk factors for HCC. This suggests that this pathologic process (necroinflammatory disease) may be hepatocarcinogenic regardless of the inciting agent. Thus hepadnavirus infection may play an important role in the development of HCC by causing chronic hepatitis and HCC with the same mechanisms by which other risk factors for HCC cause chronic necroinflammatory liver disease and HCC.
...
PMID:Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma. 819 85
Integrated
hepatitis B
virus DNA cloned from
hepatitis B
virus-associated hepatocellular carcinoma frequently contains 3'-truncated middle surface genes (preS2/St), which were recently found to have a transcriptional transactivator function. Because preS2/St, among others, is able to transactivate the promoters of the cellular oncogenes
c-myc
and c-fos, it has been speculated that integrated preS2/St genes might contribute to
hepatitis B
virus-associated liver carcinogenesis. In this study, we investigated the mechanism of target gene stimulation by preS2/St. It was found that deletion of a fragment containing the binding site for transcription factor AP-1 (Jun-Fos) substantially decreases inducibility of the human
c-myc
promoter by preS2/St. A subsequent investigation of AP-1 activation by preS2/St revealed the following: (a) insertion of multimeric AP-1 binding sites confers inducibility to an otherwise unstimulatable test promoter; (b) transactivation of AP-1 sites is dramatically increased when Jun and Fos are overexpressed by cotransfected expression plasmids; and (c) inhibitors of AP-1 activation also impair transactivation by preS2/St. Besides AP-1, preS2/St was also able to utilize the unrelated transcription factors NF-kappa B and AP-2 for transactivation, suggesting that the gene product of preS2/St acts indirectly through one or several general cellular pathways rather than as a bona fide transcription factor. Because AP-1 conveys induction of a large panel of tumor-relevant genes, its preS2/St-dependent activation implies a possible causative role in
hepatitis B
virus-associated hepatocarcinogenesis.
...
PMID:The hepatitis B virus preS2/St transactivator utilizes AP-1 and other transcription factors for transactivation. 827 60
A mammalian protein called RFX or NF-X binds to the X box (or X1 box) in the promoters of a number of major histocompatibility (MHC) class II genes. In this study, RFX was shown to have the same DNA-binding specificity as methylated DNA-binding protein (MDBP), and its own cDNA was found to contain a binding site for MDBP in the leader region. MDBP is a ubiquitous mammalian protein that binds to certain DNA sequences preferentially when they are CpG methylated and to other related sequences, like the X box, irrespective of DNA methylation. MDBP from HeLa and Raji cells formed DNA-protein complexes with X-box oligonucleotides that coelectrophoresed with those containing standard MDBP sites. Furthermore, MDBP and X-box oligonucleotides cross-competed for the formation of these DNA-protein complexes. DNA-protein complexes obtained with MDBP sites displayed the same partial supershifting with an antiserum directed to the N terminus of RFX seen for complexes containing an X-box oligonucleotide. Also, the in vitro-transcribed-translated product of a recombinant RFX cDNA bound specifically to MDBP ligands and displayed the DNA methylation-dependent binding of MDBP. RFX therefore contains MDBP activity and thereby also EF-C, EP, and MIF activities that are indistinguishable from MDBP and that bind to methylation-independent sites in the transcriptional enhancers of polyomavirus and
hepatitis B
virus and to an intron of
c-myc
.
...
PMID:The major histocompatibility complex class II promoter-binding protein RFX (NF-X) is a methylated DNA-binding protein. 841 74
The
hepatitis B
virus (HBV) X protein (pX) stimulates transcription regulated by cis-acting elements that control many viral and cellular genes, including the
c-myc
and the c-fos proto-oncogenes. Using several c-fos promoter deletion mutants, we found the serum-responsive element (SRE) located at -315, the modified TPA-responsive element located at -296 (fos-AP-1 binding site, FAP) and the region spanning from nucleotide -220 to -120, which contains an NF1-like site and several stretches of sequence homologous to the AP-2 consensus binding sites, to be responsive to pX. pX does not modify the pattern of the retarded complexes bound to the SRE/FAP region which, in our system, appears to be occupied by SRE-binding factors. The activation of the SRE does not involve complex formation between SRE-binding factors and pX, it is not associated with an increase in serum response factor binding to the SRE and it does not determine changes in SRE mobility-shift pattern.
...
PMID:The hepatitis B virus (HBV) pX transactivates the c-fos promoter through multiple cis-acting elements. 850 80
Sequences of the
Hepatitis B
virus X (HBx) gene are preferentially retained on chromosomally integrated viral DNA and thereby the precore/core promoter as a part of its reading frame. The existence of a second promoter mapping to the same DNA region is suggested by an antisense (AS) RNA which has been described earlier by Standring's group. Here, the capacity of sequences upstream to this AS RNA to function as a bidirectional promoter was analyzed. On a cloned monomer of viral DNA a segment spanning the start codon of the HBx gene and a site within the HBx frame was replaced by a luciferase reporter gene (Photinus pyralis) plus a downstream polyadenylation signal of SV40 origin. Insertion in HBx and AS orientation allowed to compare the apparent strengths of the respective promoter activities. Both DNA constructs expressed luciferase to levels above the one induced by a reference plasmid expressing the gene under control of the SV40 promoter. In the context of a reporter plasmid a 241-bp subregion of the HBx gene with enhancer II in its center part functioned bidirectionally as AS and as core promoter. For the expression of a putative AS factor two effector plasmids driven by the autologous and a heterologous promoter, respectively, were established which stimulated in co-transfection experiments a
c-myc
target gene to a higher degree than a corresponding HBx effector construct.
...
PMID:An antisense promoter within the hepatitis B virus X gene. 868 7
We previously demonstrated that MIBP1 and RFX1 polypeptides associate in vivo to form a complex that binds to the MIF-1 element in the
c-myc
gene and the major histocompatibility complex class II X-box recognition sequence. We now show that the EP element, a key regulatory sequence within
hepatitis B
virus enhancer I, also associates with MIBP1 and RFX1. Using polyclonal antisera directed against either oligonucleotide-purified MIBP1 or a peptide derived from the major histocompatibility complex class II promoter-binding protein RFX1, we showed that MIBP1 and RFX1 are both present in the DNA-protein complexes at the EP site. In addition, while the EP element can act cooperatively with several adjacent elements to transactivate
hepatitis B
virus expression, we demonstrated that the EP site alone can repress transcription of simian virus 40 promoter in a position- and orientation-independent manner, suggesting a silencer function in hepatocarcinoma cells.
...
PMID:Interactions of the transcription factors MIBP1 and RFX1 with the EP element of the hepatitis B virus enhancer. 870 29
<< Previous
1
2
3
4
5
6
Next >>